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Introduction
Diabetes mellitus refers to a group of metabolic diseases characterized by chronically elevated plasma glucose levels due to defects in insulin secretion and/or action. Long-term hyperglycaemia contributes to various complications, of which the most common is diabetic neuropathic pain (DNP), including spontaneous pain, hyperalgesia, allodynia, or other typical allodynias, rendering a profound effect on quality of life inpatients and expenditures for health care [1, 2] . DNP can also be described as a painful numbness, burning, or a stabbing sensation in the "stocking and glove" distribution [3] . The symptoms of DNP can be debilitating and may cause sleep disturbance and anxiety and interfere with physical functioning [4] . Epidemiological studies show that around 60% of diabetic patients are complicated with diabetic neuropathy, with a DNP incidence of 40% to 50% [5] [6] [7] . Seventy-three point six percent of patients with type II diabetes mellitus complicated with neuropathic pain had a pain history of over a year. Of these patients, 61.4% described pain accompanied with a tingling or stabbing of the skin, and 55% experienced numbness or were hypersensitive to stimuli [8] . So far, DNP remains a prevalent and persistent clinical challenge due to its complexity of pathogenesis.
Conventional regimens for DNP are mainly focused on control of blood glucose and relief of pain. The drugs available include atricyclic antidepressant (amitriptyline) and anticonvulsants (phenytoin sodium, carbamazepine, gabapentin, etc.) [9] . However, due to the pharmacological interactions of these agents with a-adrenegic, H1-histamine, muscarinic cholinergic, and N-methyl-Daspartate receptors, there is a high incidence of adverse events and poor tolerance in patients.
Duloxetine was approved for DNP by the US Food and Drug Administration in 2004 based on large randomized controlled trials. In the first placebo-controlled doubleblind trial, patients receiving duloxetine at 60 mg and 120 mg reported a significant decrease in average pain scores throughout the study [10] . In the United Kingdom, duloxetine was reported to be cost-effective for DNP, hence its endorsement by NICE (Clinical Guideline 173) in November 2013 [11] . Its common side effects were nausea, somnolence, dizziness, dry mouth, constipation, and loss of appetite. The adverse reactions are mild or moderate and are usually temporary. Despite the encouraging clinical efficacy of duloxetine in diabetic patients with neuropathic pain, the exact mechanism has not been unveiled.
Toll-like receptors (TLRs), a family of pathogen recognition receptors of the innate immune system, are reportedly expressed by a multitude of immune cells, including CNS microglia. TLR4 is a type I transmembrane receptor involved in the recognition of pathogeninduced immune responses and is reportedly expressed in glial cells in the central nervous system [12] . Its biological functionality mainly depends on the potent TLR4 signal pathways, that is, Myd88-dependent and -independent pathways, with the former mainly mediated by NF-jB activation and cytokine production, whereas the latter, via TRAM-TRIF, PI3K, p38, MAPK, and JNK signaling pathways, perform vital physiological functions [13] [14] [15] [16] . TLR4 also contributes to neuropathic pain via the activation of glial cells [17] . Spinal glial cells (microglia and astrocytes) are pivotal in the origination and development of neuropathic pain [18] , in which NF-jB can promote microglia to release neuronal active substances and proinflammatory cytokines to initiate and sustain neuropathic pain. Therefore, it would be plausible to inhibit the TLR4 signaling pathway to address diabetic neuropathic pain, which may bring prospects for novel strategies for the therapeutics of DNP.
The present study was designed to establish the rat model of type 1 diabetic neuropathic pain, involving behavioral tests, immunohistochemistry, and Western blot techniques to explore the effect of TLR4, Myd88, and NF-jB in DNP and reveal the mechanism of duloxetine in relieving DNP. Our experiment aimed to provide some insight into the experimental guidance and clinical applications of duloxetine in the treatment of DNP as well as shed light on new drug targets for further usage.
Methods

Materials
Two hundred male Sprague-Dawley rats, average body weight 180 to 220 g (Experimental Animal Center, Xuzhou Medical University), were randomized into four groups: control group (group C), diabetic neuropathic pain group (group DNP), vehicle control group (group SC þ DNP), DNP þ duloxetine group (group DLX þ DNP; N ¼ 27 each). All experiments were in accordance with the guidelines of the International Association for the Study of Pain, with the approval of the Institutional Committee for the Ethical Use of Laboratory Animals. For the establishment of the rat model of type 1 diabetic neuropathic pain, rats underwent measurement of basal pain threshold and intraperitoneal injection of STZ (65 mg/kg). Three days later, blood glucose from the caudal vein was stably greater than 16.7 mmol/L, and on day 14 after administration of STZ, the measured pain threshold declined until it was greater than 20% of the basal pain threshold, when DNP models were successfully prepared. STZ dissolved in sodium citrate buffer 0.1 mol/L (freshly prepared in ice bath, pH 4.5) was intraperitoneally injected in model rats, with an identical dose of sodium citrate buffer solution administered in the control group. Mechanical withdrawal threshold (MWT) and withdrawal reflex thermal latency (WTL) were measured one day before STZ injection and at three, seven, 10, 14, 21, and 28 days thereafter. All the behavioral tests were performed between 9 AM and 4 PM. Group SC þ DNP and group DLX þ DNP were injected with duloxetine 5, 10, and 20 mg/kg, or identical doses of normal saline, once daily for seven consecutive days; that is, the duloxetine injection occurred from day 15 through day 21 after STZ induction. Moreover, our prior report [19] confirmed that the nociceptive threshold in the DNP rat model was at the nadir and remained stable at 21 days after STZ administration; thereby, we designated behavioral testing at one hour after DLX administration, as well as determination of the TLR4, Myd88, and NfkB expressions, to further verify our hypothesis.
Effects of Duloxetine on TLR4
Measurement of Mechanical Withdrawal Threshold
The mechanical paw withdrawal threshold was recorded one day prior to STZ administration (baseline, day -1) and at days 3, 7, 14, 17, 21, and 28 subsequent to STZ injection. With a positive response to the stimulus, the subsequent scale of von Frey filaments was applied, and in the case of a negative response, the proximate incremental filament was applied.
Measurement of Thermal Withdrawal Latency
Thermal withdrawal latency (TWL) was measured using the IITC 336 plantar/tail flick test. The rats were placed on a 6 mm-thick glass plate, with thermal radiation applied to the plantar pad, with the duration from irradiation to paw withdrawal recorded. The TWL test was performed five times at an interval of five minutes, with the values from the final three tests averaged as TWL.
Immunohistochemistry
Rats in the four groups for behavioral tests also underwent histological analyses. Briefly, the rats under anesthesia were transcardially perfused with 4% buffered paraformaldehyde on day 21 after STZ administration. The spinal cord was collected and subsequently fixed in 4% paraformaldehyde, embedded in optimum cutting temperature compound, and sliced at a thickness of 35 mm, followed by incubation of the spinal cord with 10% H 2 O 2 for 10 minutes. After blockage with 10% goat serum, sections were stored overnight at 4 C with addition of rabbit polyclonal antibodies against TLR4 (1:100 Abcam), Myd88 (1:100 Abcam), NF-jB (1:100 CST). Thereafter, sections were stained using the twostep substance P supersensitivity method. The expressions of TLR4, Myd88, and NF-jB in the spinal cord dorsal horn were microscopically examined, where positive staining was visualized as brown-yellow granules. Six slides of dorsal horn from each rat were chosen, with the population of positively stained cells in the spinal cord dorsal horn calculated.
Western Blot
At the end of the MWT measurements, the remaining six rats in each group were sacrificed, followed by isolation of the L4-6 spinal cords and storage in liquid nitrogen or at -80 C for subsequent procedures. The frozen spinal cords were directly homogenized in a lysis buffer containing a cocktail of protease inhibitors. Following 15-minute centrifugation at 12,000 rpm at 4 C, the supernatant was collected for Western blotting. Equal amounts of protein (30 mg) were loaded in each lane and separated by 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis. The resolved proteins were transferred to polyvinylidene difluoride (PVDF) membranes (Millipore, USA). The membranes were blocked in 3% bovine serum albumin (BSA) for two hours and then rinsed three times in washing buffer for five minutes each. Following sequential incubation overnight at 4 C with rabbit anti-TLR4 (1:250), rabbit anti-Myd88 (1:250), rabbit anti-NF-jB (1:250), and mouse anti-b-actin (1:1000) primary antibody, the blots were rinsed three times in washing buffer for five minutes each and incubated for one hour with HRPconjugated goat antirabbit IgG (1:1,000) or goat antimouse secondary antibody IgG (1:1,000). The blots were rinsed in washing buffer six times for five minutes, followed by visualization using ECL and exposure onto X-films for one to 10 minutes. All Western blot analyses were performed at least in triplicate, with parallel results obtained. Squares of the same size from each band were measured for density, with the background subtracted. The expression of b-actin was used as a loading control for protein expression. The expression level of the proteins is an average of the density per band area from each group.
Statistical Analysis
The data are expressed as the mean þ SEM. Time courses measured for MWT were analyzed by two-way analysis of variance (ANOVA), followed by the NewmanKeuls post hoc test. Western blot and immunofluorescence analysis were performed by one-way ANOVA. A P value of less than 0.05 was considered statistically significant. All the tests (including behavior, Western blotting, and immunofluorescence) were performed blindly.
Results
Blood Glucose Levels in Rats
Compared with the control group, the blood glucose levels in groups DNP, SC þ DNP, and DLX þ DNP were significantly increased to meet diagnostic criteria for diabetes mellitus after intraperitoneal injection of STZ (P < 0.05) (Figure 1 , Table 1 ).
Measurements of Mechanical Withdrawal Threshold and Thermal Withdrawal Latency in Rats
STZ-induced DNP rats showed a significant decline in MWT as of day 3 after intraperitoneal injection, and they maintained a plateau throughout the experiment compared with the control group (P < 0.05). The DLX þ DNP group had a rise in MWT from day 3 after intraperitoneal injection of duloxetine vs the DNP and SC þ DNP groups (P < 0.05) (Figure 2 ).
The thermal withdrawal latency was assessed in the control, DNP, SC þ DNP, and DLX þ DNP groups. STZinduced DNP rats showed a significant decline in TWL as of day 3 after intraperitoneal injection, and they maintained a plateau throughout the experiment vs the control group (P < 0.05). The DLX þ DNP group had a rise in TWL as of day 3 after intraperitoneal injection of duloxetine vs the DNP and SC þ DNP groups (P < 0.05) (Figure 3) .
Expressions of TLR4, Myd88, and NF-jB in Rats
Immunohistochemistry and Western blot showed upregulated expressions of TLR4, Myd88, and NF-jB in the DNP, SC þ DNP, and DLX þ DNP groups (P < 0.05). In the control group, all the proteins were underexpressed. The expressions of TLR4, Myd88, and NF-jB in the spinal dorsal horn in group DLX þ DNP were downregulated vs the DNP group. There were no significant differences in expression levels between the DNP and SC þ DNP groups (P > 0.05) (Figures 4 and 5) .
Discussion
Diabetes mellitus is a disease with a high disability rate, which gradually increases with the aging of the population. Patients with either type 1 or type 2 diabetes mellitus have an incidence of more than 50% diabetic neuropathy, with painful diabetic neuropathy being one of the most serious complications and seriously affecting the quality of life in such patients. Diabetic neuropathic pain (DNP) is mainly manifested as allodynia and hyperalgesia; that is, even normal non-nociceptive stimulation can evoke pain and can be more sensitive to normal stimulation. At present, the pathogenesis of DNP has not been fully elucidated. In addition to inflammatory pain and other painful neuropathies, neuropathic pain, characterized by spontaneous pain such as hyperalgesia and allodynia, is a major concern in the field of pain treatment [20] . Moreover, DNP often coexists with sleep disorder and depression [21] .
Experimental animal models of DNP can mimic the symptoms of the patients, including spontaneous pain as well as reduced pain thresholds to mechanical and thermal stimulations. The study of the pathogenesis of DNP mostly rests on animal models. Despite their drawbacks and limitations, animal models are still useful aids to the understanding and exploration of the pathogenesis of neuropathic pain in humans. At present, the methodology of animal models of DNP consists of pancreatic resection, T cell induction as well as chemotherapy induction involving streptozotocin (STZ), tetraoxypyrimidine, cyclophosphamide, and some biological agents, of which induction by chemical agents is the most convenient and effective method for selective destruction of pancreatic b cells. STZ is able to induce many diabetic animal models via selective destruction of pancreatic islet beta cells in certain species of animals, such as rats and mice. STZ has relatively low toxicity and a high survival rate; thus it is widely used in the preparation of the diabetic animal model. The DNP model used in this experiment was induced by STZ (65 mg/kg, i.p.) [22] . Compared with the control group, the MWT and TWL in the DNP, SC þ DNP, and DLX þ DNP groups began to decrease three days after STZ injection and were significantly lower than their basal values at two weeks after STZ administration, which prompted successful preparation of the DNP model.
TLRs serve as an important mediator in inflammatory and neuropathic pain [23] and play important roles in the pathogenesis of neuropathic pain due to spinal cord inflammation and immune response. TLRs are expressed by many cell types in the central nerve system (CNS) and peripheral nerve system (PNS), including non-neuronal cells (e.g., microglia, astrocytes, oligodendrocytes, and Schwann cells) and neurons, one of which, TLR4, is reportedly expressed in primary sensory neurons [24] , microglia, and astrocytes [25] . Once bound to ligands, either endogenous or exogenous in origin, TLR4 is overexpressed, which activates NF-jB and transitively activates microglia in the central nervous system, resulting in the release of pro-inflammatory cytokines [26] [27] [28] such as TNF-a, IL-1, and IL-10, all contributing to the onset and persistence of DNP [29, 30] . Meanwhile, the TLR4 expression is synchronous with MWT and TWL. Also, TLR4 mRNA is reportedly upregulated in rats with DNP induced by STZ administration 14d 17d 21d 28d Figure 3 The development of thermal hyperalgesia in groups control, DNP, SC þ DNP, DLX þ DNP (5 mg/kg), DLX þ DNP (10 mg/kg), and DLX þ DNP (20 mg/kg; N ¼ 27, *P < 0.05). The mechanical TWL decreased in diabetic groups but was reversed in DLX-injected groups. The alteration of thermal hyperalgesia was detected after DLX injection in the hind paws in rats on days 17 and 21 of behavioral testing. 14d 17d 21d 28d Figure 2 The development of mechanical allodynia in groups control, DNP, SC þ DNP, DLX þ DNP (5 mg/kg), DLX þ DNP (10 mg/kg), and DLX þ DNP (20 mg/kg; N ¼ 27, *P < 0.05). The mechanical MWT decreased in diabetic groups but was reversed in DLX-injected groups. The alteration of mechanical allodynia was detected after DLX injection in the hind paws of rats on days 17 and 21 of behavioral testing.
[31], coupled with significant upregulation of the expressions of pro-inflammatory cytokines TNF-a and IL-1 downstream of the TLR4 signal transduction pathway. MyD88 plays a key role in the TLR4 pathway in DNP mice, and MyD88 is reportedly upregulated by 50% in mice lacking MWT compared with the control group [32] . These findings suggest that the TLR4 signal transduction pathway is implicated in DNP. In our present experiment, the expressions of TLR4, Myd88, and NFjB were upregulated in the spinal dorsal horn in the DNP, SC þ DNP, and DLX þ DNP groups subsequent to intraperitoneal injection of STZ, accompanied by abridged TWL and WMT as compared with the control group, which affirmed the involvement of the TLR4-MyD88-NF-jB signal pathway in the initiation and duration of DNP, with the activated microglia and astrocytes promoting the release of pro-inflammatory cytokines to induce and maintain DNP, thus illuminating a novel strategy for the treatment of DNP by the inhibition of the TLR4 pathway.
Duloxetine (trade name: Cymbalta, Eli Lilly and Co.), a kind of 5-hydroxytryptamine (5-HT) and norepinephrine (NE) reuptake inhibitors (SNRI) [33, 34] , now serves as an antidepressant available for the treatment of severe depression disorders and DNP, as well as moderate to severe stress urinary incontinence in women. 5-selective serotonin reuptake inhibitors (SSRIs) can reportedly inhibit the activation of microglia and secretion of TNF-a and IL-6. Duloxetine has been shown to increase 5-HT and NE concentration in the brain and spinal cord and enhance tolerance to pain and reduce the pain symptoms in patients in clinical trials, whereas the depressive symptoms were not mitigated [35] . In our experiment, blood glucose did not differ between the DNP and DLX þ DNP groups after intraperitoneal injection of Figure 4 Expressions of TLR4, Myd88, and NF-jB in groups DNP, SC þ DNP, and DLX þ DNP by immunohistochemistry. Quantitative analysis by immunohistochemistry revealed expressions of TLR4, Myd88, and NF-jB in spinal dorsal horn were upregulated in groups DNP and SC þ DNP and downregulated in the DLX þ DNP group (N ¼ 6, *P < 0.05, scale bar ¼ 200 mm). In the control group, the proteins were underexpressed. duloxetine, which is supported by our prior findings that duloxetine could not decrease blood glucose concentration, which excepted the correlation between blood glucose and the analgesic effect. Brain-derived neurotrophic factor (BDNF) in the spinal cord and dorsal root ganglion is well acknowledged to be a critical neuromodulator, and BDNF antagonists inhibit the central sensitization. Duloxetine can increase the concentration of 5-HT and NE in the synaptic cleft, while 5-HT and NE can regulate the level of BDNF in the brain, resulting in rapid initiation of analgesic effect. The dose of duloxetine in rats was based on clinical dose in humans by conversion formula. In this experiment, MWT began to increase and TWL began to extend three days after intraperitoneal injection of duloxetine, in parallel with the downregulation of TLR4, Myd88, and NF-jB expression. We postulated that duloxetine inhibited the expressions of TLR4, MyD88, and NF-jB to inhibit the activation of microglia and astrocytes as well as the release of inflammatory cytokines, which putatively attributes to the modulation of 5-HT and BDNF. Our findings demonstrated that intraperitoneal injection of duloxetine can effectively elevate the pain threshold and downregulate the expression of TLR4, Myd88, and NFjB to relieve diabetic neuropathic pain, presumably via the inhibition of the TLR4-Myd88-NF-jB signaling pathway.
Conclusions
In conclusion, despite the complexity of the pathogenesis of DNP and paucity of specific therapy available, our findings confirmed that duloxetine reduced mechanical and thermal withdrawal thresholds and overexpression of the TLR4-Myd88-dependent pathway in the spinal dorsal horn in STZ-injected rats. However, whether the modulation of the TLR4-Myd88-NF-jB signaling pathway by duloxetine in DNP rats directly contributed to the reduction of thermal and mechanical withdrawal behavior awaits further investigation. Our findings might Figure 5 Expressions of TLR4, Myd88, and NF-jB in groups DNP, SC þ DNP, and DLX þ DNP (N ¼ 7, P < 0.05) by Western blotting (upper panel). Quantitative analysis by Western blotting revealed that expressions of TLR4, Myd88, and NF-jB were upregulated in groups DNP and SC þ DNP and downregulated in the DLX þ DNP group (N ¼ 7, *P < 0.05). In the control group, the proteins were underexpressed.
